Miconazole
| Evidence Level: L3 | Predicted Indications: 1 |
Table of Contents
Miconazole: From Fungal Infections to Acne
One-Sentence Summary
Miconazole is a well-established imidazole antifungal, most familiar as a topical and vaginal treatment for dermatophyte and candida infections. The TxGNN model predicts it may be effective for Acne, though this direction is currently supported by only 1 clinical trial (suspended, evaluating a related combination product) and 4 publications, most of which are mechanistic or observational in nature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in this evidence pack (miconazole is an established azole antifungal; specific licensed indication text unavailable) |
| Predicted New Indication | Acne |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for miconazole in this evidence pack. Based on established pharmacological knowledge, miconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis in the fungal cell membrane. It is most commonly formulated for topical or vaginal use against dermatophyte and Candida infections.
The link to acne is mechanistic rather than derived from the drug’s approved indication. Literature identified in this pack (PMID 20045949) reports that azole antifungals, including miconazole, show in vitro activity against Propionibacterium acnes, the bacterium implicated in acne vulgaris. Separately, PMID 8593718 highlights that Pityrosporum (Malassezia) folliculitis — a fungal condition — is frequently misdiagnosed clinically as acne vulgaris, suggesting a subset of “acneiform” presentations may respond to antifungal therapy. A dedicated review (PMID 18627330) further discusses miconazole’s broader effects on skin disorders beyond classical antifungal use.
Taken together, the rationale is that miconazole’s dual antifungal and antibacterial (anti-P. acnes) activity could be relevant to acneiform conditions with a fungal or mixed microbial component, rather than to typical bacterial acne vulgaris as a whole. This is a narrower and more mechanistically specific hypothesis than a general repurposing claim, and it has not yet been tested in a completed clinical trial of miconazole itself for acne.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01244256 | Phase 2/3 | Suspended | 80 | Evaluated a combination cream (clotrimazole 1% + gentamicin 0.1% + beclometasone 0.025%) in patients with contaminated dermatosis showing bilateral symmetrical lesions (“acne”-labelled cohort); trial was suspended and did not evaluate miconazole directly |
Note: this trial studies a related azole antifungal (clotrimazole) in combination, not miconazole itself, and did not reach completion.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18627330 | 2008 | Review | Expert Opinion on Pharmacotherapy | Reviews novel effects of miconazole nitrate, a long-established azole antifungal, on various skin disorders |
| 15536660 | 2004 | Clinical/bioinstrumental study | Skin Research and Technology | Split-face assessment of mild inflammatory catamenial (hormone-related) acne; notes oral contraceptives may help but do not clear the skin condition |
| 20045949 | 2010 | In vitro study | Biological & Pharmaceutical Bulletin | Azole antifungals, including miconazole, show in vitro activity against Propionibacterium acnes, the causative bacterium of acne vulgaris, amid rising antibiotic resistance |
| 8593718 | 1995 | Case series/diagnostic study | Clinical and Experimental Dermatology | Pityrosporum (Malassezia) folliculitis in 62 patients, frequently misdiagnosed as acne vulgaris, confirmed by histology and microscopy |
UK Market Information
Miconazole currently holds no UK marketing authorisation in this evidence pack (market status: not marketed; total licenses: 0). No product-level authorisation data is available for review.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence for miconazole in acne is preliminary and largely mechanistic — the single identified trial was suspended and did not test miconazole directly, and the literature consists mainly of in vitro, observational, and review-level findings rather than completed clinical trials of miconazole for acne. Miconazole also currently holds no UK marketing authorisation, and no safety or warning data are available for evaluation.
To proceed, the following is needed:
- Confirmed mechanism of action data (DrugBank) and specific licensed original indication text
- SmPC-level warnings, contraindications, and drug interaction data (currently a blocking gap)
- A completed, prospective clinical trial evaluating miconazole itself (not a related azole in combination) for acne or fungal-associated acneiform conditions
- Confirmation of any pathway to UK marketing authorisation for a new indication, given the drug is not currently marketed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.